Shape the future of
cell therapy

Whether it is a career, a partnership, or an investment, join us to unleash the potential of cell therapy together

We are actively adding to our team
Image of scientists in a laboratory examining a sample


At Legend Biotech, we are transforming the world of oncology and medicine, and always looking for people who can help contribute to the strength of our team and to our shared values.

We are actively hiring across multiple functions and levels to strengthen our world-class team with our goal and commitment to improving patients' lives through transformative science and medicine.

To view and apply for one of our current open positions, visit our LinkedIn Careers page.

Current partnerships

In collaboration with Janssen Biotech, Inc.

Legend Biotech has entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture, and commercialize LCAR-B38M (JNJ-68284528/JNJ-4528). Under the terms of the agreement, Legend and Janssen are co-developing and will co-commercialize LCAR-B38M/JNJ-4528 in select countries. Manufacturing of LCAR-B38M/JNJ-4528 for commercial distribution worldwide will be done in partnership with Janssen.

Legend received clearance from China National Medical Products Administration in March 2018 for a Phase 2 registration study in China, and Janssen Biotech, Inc. received US Food and Drug Administration clearance for an Investigational New Drug Application in May 2018 and has since initiated a Phase 1b/2 study intended for registration in the United States and EU.

JNJ-4528 was granted Orphan designation by the US FDA in February 2019 followed by PRIME designation in the EU by the EMA in April 2019.


Partnership Opportunities

Contact Us

Contact Information


Country of origin

Select your topics of interest

Selection Required
Commercial (including sales & marketing)
Research and development
Clinical trials (including regulatory)
Investment opportunities
Grant and CME requests

Reason for contact

Would you like to receive the latest news, updates, and communications from Legend Biotech? (optional)

By checking this box, you agree to receive communications from Legend Biotech not limited to your selected area of expertise. You may opt-out at any time if you no longer wish to participate.


The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

*LCAR-B38M identifies the investigational product being studied in China and Janssen Biotech, Inc.'s JNJ-68284528 (also referenced as JNJ-4528) identifies the investigational product being studied in the United States, both of which are representative of the same CAR-T cell therapy.


But we are just getting started!

You are about to leave
Are you sure you want to leave so soon?


By continuing to use our site, you agree to terms on our Legal Notice.
You can learn more about how we use cookies by viewing our Legal Notice.